SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has traders focused on Starknets privacy and Bitcoin DeFi plans, alongside its STARK-based post-quantum security narrative. Bullish momentum and ecosystem optimism are tempered by concerns about token unlocks, selling pressure, and whether the move is a short-lived pump.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a recent price rebound, with traders debating whether the move can continue or give way to another pullback. Bulls point to Bittensors decentralized-AI ecosystem and subnet development, while cautious voices question adoption and near-term catalysts amid broader crypto and macro uncertainty.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being tied to a weak housing markethigh mortgage rates and affordability pressures are weighing on transactionswith lowered guidance adding to concerns despite revenue growth. Bearish traders see further downside, while bulls argue the shares are oversold and point to growth in rentals, mortgages and AI-enabled products.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Attention centers on Compounds institutional-market push, including a reported launch, new leadership and investment plans, alongside anticipation for V4. Many traders are bullish on COMPs limited supply and potential breakout, while skeptics point to weak relative price action and concerns about protocol liquidity.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is drawing attention after a recent rise in trading activity, with traders comparing the companys Niemann-Pick franchise to IntraBios reported acquisition and arguing that Zevra may be undervalued; some speculate about a potential buyer, but no deal is confirmed. The discussion also points to the pending European re-examination and upcoming results, with views divided over regulatory prospects and the stocks gains.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual trading powered by Hyperliquid, with traders also highlighting the tokens AI-agent and cross-chain Intents narrative. The reaction is largely bullish, though some remain cautious about pullbacks and the earlier NEAR Intents exploit.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

A Brazilian federal appeals court restored Sigma Lithiums existing mining licenses, allowing operations to resume after a shutdown. Traders welcomed the restart, while noting that the plant expansion remains blocked pending a community-related survey, leaving legal and execution risks in focus.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and consolidation are driving IBIT discussion, with many traders treating pullbacks as buying opportunities and anticipating further gains, while others warn that momentum could fade. The conversation is largely about Bitcoins direction rather than a confirmed IBIT-specific catalyst.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are drawing attention as traders assess whether GDXs correction is bottoming, with higher real yields and a stronger dollar cited as near-term pressure on gold and miners. Some see signs of a rebound and are buying dips, while others want confirmation and warn that the pullback may continue; longer-term bulls point to central-bank buying and concerns about debt and currency debasement.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

XCN is drawing attention amid a modest rebound and ongoing consolidation, with traders focused on chart levels, returning volume and the prospect of a breakout. Some are buying dips and expecting momentum to build, while others warn that thin volume and repeated rallies that fade make the move look like a pump-and-dump; broader crypto-market weakness is also cited.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q4 results 2026: BHEL to Paytm among firms to declare Q4 earnings next week

… Fincorp 11 Ajanta Pharma 12 Emcure Pharmaceuticals 13 Aadhar Housing … Kriti Nutrients 46 Jenburkt Pharma 47 Kriti Industries (India) … Coast Hotels 61 Sandu Pharmaceuticals 62 Premier Energy and … STL Networks 39 Shukra Pharmaceuticals 40 Alldigi Tech 41 …

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka

India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging among millions needing obesity management. Broader specialist adoption and a growing prescriber base are fueling this expansion, promising substantial market growth.

India’s Cheap Ozempic Moment Is Here: Ozempic Prices Set to Drop to ₹3,000 as Semaglutide Goes Off-Patent in India

… in the highly successful weight-loss drugs called “Ozempic” and “Wegovy” developed … such as Mankind Pharma Ltd., Ajanta Pharma Ltd., Sun Pharmaceutical Industries Ltd. and … nearly 20% of all generic drugs available globally. The most significant impact …

Raja Venkatraman, MarketSmith India recommends five stocks for 16 March

On March 13, Indian stock indices Sensex and Nifty 50 faced continued selling pressure due to rising crude oil prices and global economic concerns. GIFT Nifty today suggests a mildly positive start, with several stocks recommended for buying, including Ajanta Pharma and Power Grid Corporation.

Everstone to sell stake in Restaurant Brands Asia – report

The family office of the founders of Ajanta Pharma in India may inject up to Rs8bn ($88m) into RBA.

Everstone to sell entire stake in India's Burger King operator Restaurant Brands Asia, sources say

Private equity firm Everstone is set to exit Restaurant Brands Asia, the franchisee for Burger King in India and Indonesia. The firm will sell its entire 11.26% stake. The Ajanta Pharma family office is poised to become the new strategic investor. This move could see the family office injecting significant funds and potentially acquiring a majority stake in the company.

India’s Ajanta Pharma eyes Irish manufacturing base

Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.

Biocon to supply semaglutide to Ajanta for marketing in 26 countries

Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically integrated drug product, semaglutide, used to improve glycemic control in adults with type-2 diabetes.

Indian equity benchmarks end flat in thin year-end trade; IT losses weigh

India’s equity benchmarks closed little changed on Wednesday in a subdued session marked by thin year-end volumes, with losses in information technology stocks weighing on sentiment. The Nifty 50 fell 0.13% to 26,142.1, while the BSE Sensex shed 0.14% to 85,408.7. Fifteen of the 16 major sectors declined. Small-caps rose 0.3%, while mid-caps fell 0.6%. Analysts said thin year-end trading kept volatility in check, with global volumes typically light ahead of the Christmas and New Year holidays. Indian markets will be closed on Thursday for Christmas. Investors are awaiting further cues, including a potential India-U.S. trade deal and October-December earnings, for a directional trade in the market. Motilal Oswal Financial Services said the earnings revision trends in the past four months have beaten its expectations. “The backdrop for earnings has improved vs last year, engineered by a series of stimulative fiscal and monetary measures,” the brokerage firm said. IT stocks fell 0.5% on the day after U.S.

Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The firm offers branded generics that serve a range of therapeutic segments such as antibiotic, anti-malarial, anti-diabetic, cardiology, gynecology, orthopedics, pediatric, respiratory, and general health. It operates through the following geographical segments: India, Africa, Asia, and USA. The company was founded by Purushottam Bhagwand Agrawal in 1973 and is headquartered in Mumbai, India.

Current Price	3,405.00
Prev Close	3,435.00
Open	3,437.90
Dividend Yield	1.00%
50-Day Moving Average	3,547.04
Beta	-0.08
Avg. Volume	93,506.86
PE Ratio	37.54

52-Week High	3,796.00
52-Week Low	2,380.20
Market Capitalization	426.24B
EPS (Annual)	84.53
Price to Book	9.41
Revenue Per Employee	4.11M

Feed

News

Sentiment

Fundamentals

Info

AJANTPHARM.NSE Fundamentals